Santen Pharmaceutical Asia Pte. Ltd.
1 clinical trials · Sponsor
◉ Watch Santen Pharmaceutical Asia Pte. Ltd.
| Record | Firm | Date |
|---|---|---|
| Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl (NCT05279716) | Santen Pharmaceutical Asia Pte. Ltd. | 2022-02-15 |
Track Santen Pharmaceutical Asia Pte. Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.